101P Cost-effectiveness of liquid biopsy in stage II colon cancer: A real-world analysis
V. Martelli(Ospedale Policlinico San Martino), A. Pastorino(Ospedale Policlinico San Martino), Federica Grillo(Ospedale Policlinico San Martino), Jenniffer Linares(Hospital Del Mar), V. Andretta(Ospedale Policlinico San Martino), Alessandro Gambella(Ospedale Policlinico San Martino), Alessandra Dondero(Ospedale Policlinico San Martino), J. Vidal Barrull(Parc de Salut), Sonia Lastraioli(Ospedale Policlinico San Martino), Luca Mastracci(Ospedale Policlinico San Martino), S. Mammoliti(Ospedale Policlinico San Martino), Mariella Dono(Ospedale Policlinico San Martino), Giuseppe Fornarini(Ospedale Policlinico San Martino), C. Montagut Viladot(Parc de Salut), Sabrina Beltramini(Ospedale Policlinico San Martino), Alberto F. Sobrero(Ospedale Policlinico San Martino), A. Malatto(University of Genoa), Lucia Leporatti(University of Genoa), P. Cordasco(Ospedale Policlinico San Martino), F Copello(Ospedale Policlinico San Martino)
Cited by 0
Related Papers
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
|The Lancet. Gastroenterology & hepatology|2020|249
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240